The milestone is grim; the receipt is what tells you a response exists.
The Bundibugyo-Ebola toll in the Democratic Republic of the Congo has crossed 500. The country now reports 1,561 confirmed cases and 506 deaths as of July 5, up from the 438 the paper carried a day earlier. [1] Ituri province remains the epicenter, with 1,417 cases and 424 deaths across 24 of its 36 health zones. [2] WHO's DRC representative, Dr. Anne Ancia, would not call the outbreak stabilizing: "we would like to say it is stabilising, but frankly, we cannot say it yet," and the true scale, she said, is not yet established. [1]
The paper's July 7 account of the first listed Bundibugyo diagnostic test argued that the operational unit — what is actually on the record — is a better measure of a response than any death total. Today two records advance that frame.
The first is a trial. On July 2, a clinical trial began in the DRC to identify an effective treatment, because there is no proven cure for the Bundibugyo species of Ebola. [2] It is evaluating a monoclonal antibody, MBP134, and the antiviral remdesivir — alone and in combination — for their effect on survival. A listed, enrolling trial protocol is a different kind of fact than a milestone: it is a commitment with a design, an endpoint, and patients.
The second is throughput. Testing has scaled from about 30 samples a day in Kinshasa at the outbreak's start to more than 2,000 a day across 10 decentralized laboratories. [1] Tests per day is the metric that decides whether new cases are being found or merely feared. A response is real when the diagnostic capacity is on the record, not when a number is announced.
The divergence is one of lens. On X, the outbreak is read through a gutted-CDC frame: can a U.S. agency that has shed roughly a quarter of its workforce guard a 48-city World Cup and run an elevated Ebola response at the same time? That anxiety is not baseless — federal reporting describes exactly that triage, with the CDC elevating its Ebola response while making "hard decisions" about what to prioritize. [3] Mainstream outlets, for their part, lead on the 500-death milestone and the outbreak's status as a declared public-health emergency. [1]
The paper's gap is between the milestone and the machinery. The 506 deaths measure the cost. The trial and the 2,000 daily tests measure the answer — and a reader who tracks only the toll will miss the fact that a response is being built in real time, lab by lab, even as WHO declines to say it is working yet.
This outbreak belongs to the same thread as the cyclospora surveillance gap and the World Cup measles watch: four demands on public-health capacity that is thinner than it was, tested at once. The receipt that matters is not the count. It is the trial protocol and the tests-per-day — the record that says someone is still answering.
-- KENJI NAKAMURA, Tokyo